TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01778075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol HCl 75 mg/Acetaminophen 650 mg (Newly developed ULTRACET ER)
Description: Single oral dose of newly developed ULTRACET ER, (Tramadol HCl/Acetaminophen 75/650 mg), administered under fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol HCl 75 mg/Acetaminophen 650 mg (Newly developed ULTRACET ER)
Description: Single oral dose of newly developed ULTRACET ER, (Tramadol HCl/Acetaminophen 75/650 mg), administered under fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol HCl 75 mg/Acetaminophen 650 mg (Marketed ULTRACET ER)
Description: Single oral dose of marketed ULTRACET ER, (Tramadol HCl/Acetaminophen 75/650 mg), administered under fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol HCl 75 mg/Acetaminophen 650 mg (Marketed ULTRACET ER)
Description: Single oral dose of marketed ULTRACET ER, (Tramadol HCl/Acetaminophen 75/650 mg), administered under fasted condition.
Study: NCT06090123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPN171H
Description: Sequence 1：Single dose of 10mg TPN171H on Day 1, 200mg Itraconazole(QD) on Days 3-5, 10mg TPN171H and 200mg Itraconazole on Day 6.~Sequence 2：Single dose of 20mg TPN171H on Day 1, 600mg Rifampicin(QD) on Days 3-9, 20mg TPN171H and 600mg Rifampicin on Day 10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPN171H
Description: Sequence 1：Single dose of 10mg TPN171H on Day 1, 200mg Itraconazole(QD) on Days 3-5, 10mg TPN171H and 200mg Itraconazole on Day 6.~Sequence 2：Single dose of 20mg TPN171H on Day 1, 600mg Rifampicin(QD) on Days 3-9, 20mg TPN171H and 600mg Rifampicin on Day 10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Sequence 1：Single dose of 10mg TPN171H on Day 1, 200mg Itraconazole(QD) on Days 3-5, 10mg TPN171H and 200mg Itraconazole on Day 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Sequence 2：Single dose of 20mg TPN171H on Day 1, 600mg Rifampicin(QD) on Days 3-9, 20mg TPN171H and 600mg Rifampicin on Day 10.
Study: NCT04311112

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ZA Low dose
Description: ZA low dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ZA high dose
Description: ZA high dose
Study: NCT04103112

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Graduated compression stocking
Description: Compression stockings have been used safely in the UK for about 50 years. They contain an elastic fibre designed to fit tightly around the legs. These specialist stockings are tighter around the ankle, with the level of compression gradually decreasing up the garment.~The pressure created by the stockings helps blood flow up the leg, allowing blood to flow freely to the heart and not pool in the leg which can result in pain and swelling.
Study: NCT03498131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 mg Melatonin
Description: 3 mg melatonin once each day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 mg Melatonin
Description: 5 mg Melatonin once each day
Study: NCT04713410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Regimen will be to administer prednisolone as a single dose of 60 mg/m2 once daily for 6 weeks, then 40 mg/m2 on alternate day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Regimen will be to administer prednisolone as a single dose of 60 mg/m2 once daily for 6 weeks, then 40 mg/m2 on alternate day.
Study: NCT01650831

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Modified BreathID
Description: A new modified device, compared to the originally cleared BreathID measures breath from a subject via a nasal cannula
Study: NCT04062747

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: I-gel
Description: After standard anesthesia i-Gel was placed into the patient

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ambu aura i
Description: After standard anesthesia ambu aura was placed into the patient
Study: NCT01596712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QGE031
Description: QGE031 was supplied as liquid in 2 mL vial for subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QGE031
Description: QGE031 was supplied as liquid in 2 mL vial for subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QGE031
Description: QGE031 was supplied as liquid in 2 mL vial for subcutaneous injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was supplied as liquid in 2 mL vial for subcutaneous injection.
Study: NCT02656966

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Auricular acupuncture
Description: Five ear acupuncture points: MA-IC, MA-TF1, MA-SC, MA-AT1 and MA-TG will be needled bilaterally in patients, who will wish to receive AA. Indwelling fixed New Pyonex needles (length: 1.5 mm, diameter: 0.22 mm; Seirin Corp., Shizuoka City, Japan) will be used for AA.
Study: NCT03599778

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apatinib
Description: XELOX + apatinib's MTD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: XELOX + apatinib's MTD
Study: NCT01234038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS EIF4E Rx
Description: 800 mg ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS EIF4E Rx
Description: 1000 mg ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS EIF4E Rx
Description: (Dose identified in Part 1)ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8, and 15 of each 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 200 mg/m2 administered as a 3-hour intravenous infusion on Day 1 of each 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 200 mg/m2 administered as a 3-hour intravenous infusion on Day 1 of each 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 200 mg/m2 administered as a 3-hour intravenous infusion on Day 1 of each 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 200 mg/m2 administered as a 3-hour intravenous infusion on Day 1 of each 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 6.0 mg/mL/min administered as a 1-hour intravenous infusion on Day 1 of each 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 6.0 mg/mL/min administered as a 1-hour intravenous infusion on Day 1 of each 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 6.0 mg/mL/min administered as a 1-hour intravenous infusion on Day 1 of each 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 6.0 mg/mL/min administered as a 1-hour intravenous infusion on Day 1 of each 21 day cycle
Study: NCT00610792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: 1.3 mg/m2 on Days 1, 4, 8 \& 11 every 3 weeks (1 cycle = 21 days) for up to six cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin
Description: 30 mg/m2 on Day 1 every 3 weeks (1 cycle = 21 days) for up to six cycles
Study: NCT03249324

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive-Gain Counseling (PGC)
Description: Positive-gain-based health promotion interventions capitalize on the basic human desire to maintain consistency between one's words and actions for beneficial outcomes. Participants will be asked to discuss potential adverse effects of obesity, an unhealthy diet, and sedentary behavior, as well as the benefits of maintaining a physically fit body, eating a healthy diet, and regular physical activity. They will also discuss the costs and benefits as they apply to developing children. Theoretically, discussing and reviewing these perspectives will make the mothers more apt to make healthier lifestyle choices in the future. Women randomized to the positive-gains counseling (PGC) group will have PGC sessions once during each trimester and at 2 weeks, 2 months, 4 months and 6 months postpartum. PGC participants will also receive prenatal care in accordance with the VA/DoD Guideline for the Management of Pregnancy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Women in the usual care (UC) group will receive prenatal care in accordance with the VA/DoD Guideline for the Management of Pregnancy. This entails regular clinic visits, routine blood and urine screening tests, and anticipatory guidance. Routine well-child care appointments will take place at 2-3 days, 2 weeks, 2 months, 4 months, 6 months, 9 months and 12 months after birth. During routine well-child visits, height, weight, and vital signs are measured, developmental milestones are reviewed, and a thorough physical examination is performed. Age-appropriate immunizations are provided as is parental anticipatory guidance, including the importance of breastfeeding. Participants enrolled in the UC group will receive anticipatory guidance from their primary care provider in the usual fashion. Providers will deliver this anticipatory guidance with no external cues or counseling provided by the research team.
Study: NCT04251832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Thiosulfate
Description: Ultrasound guided percutaneous lavage with and without Sodium Thiosulfate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Thiosulfate
Description: Ultrasound guided percutaneous lavage with and without Sodium Thiosulfate
Study: NCT02291133

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrochemotherapy
Description: Exploration, anesthesia, adhesiolysis, mobilization of liver, intra-operative US or CT, bleomycin administration, electroporation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cliniporator Vitae®
Description: Positioning of electrodes, 8-28 min after administration of bleomycin application of electric pulses (8 pulses, duration 100 microseconds, frequency 8 Hz with amplitude adequate to cover the whole treated lesion with electric field necessary for reversible plasma membrane permeabilization), removal of electrodes.~The maximum duration of procedure is 90 minutes, after liver mobilization.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin PHC 15 e. (United States Pharmacopeia - USP)
Description: Intravenous in bolus administration of bleomycin (15 mg/m2)
Study: NCT01875081

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Livercellgram
Description: Livercellgram~* Dosage form and appearance: White cell suspension is filled in a clear plastic syringe, and fixed with an occlude on the prefilled syringe tip ② Component: Autologous bone marrow-derived mesenchymal stem cell ③ Amount: 5X107 cells, 1-time or 2-time injection ④ Storage Method: Stored in airtight container at 20\~25℃~  * Injection Method: Directly inject into liver through hepatic artery

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Livercellgram
Description: Livercellgram~* Dosage form and appearance: White cell suspension is filled in a clear plastic syringe, and fixed with an occlude on the prefilled syringe tip ② Component: Autologous bone marrow-derived mesenchymal stem cell ③ Amount: 5X107 cells, 1-time or 2-time injection ④ Storage Method: Stored in airtight container at 20\~25℃~  * Injection Method: Directly inject into liver through hepatic artery
Study: NCT02435667

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Exercise Training
Description: 1. Aerobic Exercise~   a. Each participant will engage in 5 minutes of aerobic based exercise on an arm/leg ergometer (NuStep Cross Trainer) at an intensity of 12-14 on the Borg Rating of Perceived Exertion Scale as a warm-up prior to the exercise session and again as a cool-down at the end of the exercise session.~2. Resistance Exercise - 2 sets of 8-12 repetitions - beginning at 60% of the initial 1 RM.~   a) Leg Extension, b) Bicep Curl, c) Leg Press, d) Chest Press, e) Leg Curl, f)Seated Row (horizontal or pulldown), g) Calf Raises~3. Core Strengthening Exercises a. 5-10 minutes of stability ball and balance exercises

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: DEXA bone scan
Description: A DEXA scan that provides bone density measures.

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: DEXA bone scan
Description: A DEXA scan that provides bone density measures.
Study: NCT02134106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polymyxin B + Doripenem
Description: Standard dose of intravenous polymyxin B at 25,000U/kg body weight will be given in 2 divided doses each day with each dose infused over 2 hours and intravenous doripenem 500mg, with each dose infused over 4 hours. For patients with VAP, nebulized colistin at the dose of 2 MU 8 hourly for 5 days will be prescribed.
Study: NCT00720824

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Office routine
Description: Standard vaccine administration
Study: NCT00035477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azimilide Dihydrochloride
Description: 125 mg azimilide tablets once a day for 3 days in hospital and 125 mg azimilide tablets once a day for 6 months as outpatient

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo tablets once a day for 3 days in hospital and placebo tablets once a day for 6 months as outpatient
Study: NCT03620604

Intervention type: DEVICE
Intervention: Stress urinary incontinence surgery
Description: All patients were treated according to the Urology protocols of our unit. They were patients with stress urinary incontinence refractory to pelvic floor exercises so they underwent surgery
Study: NCT00365768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glutamine
Description: Administered orally twice daily for 21 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally twice daily for 21 days
Study: NCT02020291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Foxy-5
Study: NCT03933124

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: The Virtual Reality intervention is used for 10 minutes minimal 3 times a day on postoperative day 2-4.
Study: NCT02157168

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Community health worker
Description: Community health workers (CHWs) in Hispanic communities, often referred to as promotoras, are members of the community who use resource sharing, partnership development, education, outreach, health promotion, and disease prevention strategies to improve the health of their communities.~IG1: The intervention itself consists of a 45-minute one-on-one presentation and tailored planning session delivered by a CHW in a community setting of the new member's choosing. Presentations (in English or Spanish) will be delivered using a tablet computer or a hand held flipchart. Two booster telephone interactions will be performed at 2 and 4 months. At month 6, the participant will receive a call from the telephone interviewer to administer the informed patient choice survey.
Study: NCT03437044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: After providing written informed consent and following diagnostic angiography, patients meeting study entry criteria undergoing PCI will be randomly assigned in a 1:1 ratio to treatment with either ticagrelor or clopidogrel. Randomized treatment will be maintained for 30±3 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: After providing written informed consent and following diagnostic angiography, patients meeting study entry criteria undergoing PCI will be randomly assigned in a 1:1 ratio to treatment with either ticagrelor or clopidogrel. Randomized treatment will be maintained for 30±3 days.
Study: NCT04616404

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 500 mg of artichoke extract
Description: Tablets containing 500 mg of artichoke extract (triple standardized to contain caffeoylquinic acids ≥ 5.0%; flavonoids ≥ 1.5%; cynaropicrin ≥ 1.0%, by HPLC)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets with no active ingredient
Study: NCT03365947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARO-HBV
Description: sc injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARO-HBV
Description: sc injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARO-HBV
Description: sc injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARO-HBV
Description: sc injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARO-HBV
Description: sc injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARO-HBV
Description: sc injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARO-HBV
Description: sc injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARO-HBV
Description: sc injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARO-HBV
Description: sc injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARO-HBV
Description: sc injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARO-HBV
Description: sc injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARO-HBV
Description: sc injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARO-HBV
Description: sc injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARO-HBV
Description: sc injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARO-HBV
Description: sc injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARO-HBV
Description: sc injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARO-HBV
Description: sc injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARO-HBV
Description: sc injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Normal Saline (0.9% NaCl)
Description: sc injection
Study: NCT00859794

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fMRI
Description: Subjects will perform cognitive tasks during MRI scanning sessions to gather data about cognitive functions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuropsychological Testing
Description: Subjects will have a neuropsych evaluation as part of their standard of care for surgery. The research team is asking the subject to release their neuropsychological evaluations for analysis.
Study: NCT03365947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-56136379
Description: oral tablets
Study: NCT01496170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8931
Description: MK-8931, capsules, at a dose of 12 or 40 mg, orally, once per day for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8931
Description: MK-8931, capsules, at a dose of 12 or 40 mg, orally, once per day for 7 days
Study: NCT00859794

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Additional electrode implantation
Description: Subjects will typically have between 100-300 electrodes implanted as part of their surgery. Additional electrodes will be implanted that are able to record from smaller, more specific parts of the brain. This will allow for better understanding of how the brain is wired.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrical brain stimulation
Description: Intracranial or extracranial electrodes will be used to deliver electrical brain stimulation (amplitude 0.5-8.0mA) or sham stimulation of between 0.4 and 3000 milliseconds during cognitive task periods.
Study: NCT03000101

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 100% pomegranate juice
Description: 125 mL of 100% pomegranate juice twice daily for 12 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo beverage
Description: 125 mL of placebo beverage twice daily for 12 weeks
Study: NCT00084552

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: Patients undergo conventional intensity-modulated radiotherapy (IMRT) once daily 5 days a week for approximately 7.5 weeks.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Patients undergo conventional intensity-modulated radiotherapy (IMRT) once daily 5 days a week for approximately 7.5 weeks.
Study: NCT00812461

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: as-needed use, tablets, orally, 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalmefene
Description: 18.06 mg, as-needed use, tablets, orally, 6 months. 18.06 mg nalmefene equals 20 mg nalmefene hydrochloride.
Study: NCT01448681

Intervention type: OTHER
Intervention: No Interventions
Study: NCT04430634

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myblu variant A
Description: Use of Myblu e-cigarette with flavor A 2.4% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myblu variant A
Description: Use of Myblu e-cigarette with flavor A 2.4% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myblu variant A
Description: Use of Myblu e-cigarette with flavor A 2.4% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myblu variant A
Description: Use of Myblu e-cigarette with flavor A 2.4% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myblu variant B
Description: Use of Myblu e-cigarette with flavor B 3.6% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myblu variant B
Description: Use of Myblu e-cigarette with flavor B 3.6% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myblu variant B
Description: Use of Myblu e-cigarette with flavor B 3.6% nicotine
Study: NCT01496170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8931
Description: MK-8931, capsules, at a dose of 12 or 40 mg, orally, once per day for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules, orally, once per day for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules, orally, once per day for 7 days